Skip to main content
CASSAVA SCIENCES INC logo

CASSAVA SCIENCES INC — Investor Relations & Filings

Ticker · SAVA ISIN · US69562K5065 LEI · 529900XA0UG5JXABYF08 US Professional, scientific and technical activities
Filings indexed 1,002 across all filing types
Latest filing 2026-04-28 Regulatory Filings
Country US United States of America
Listing US SAVA

About CASSAVA SCIENCES INC

https://www.cassavasciences.com/

Cassava Sciences, Inc. is a clinical-stage biotechnology company that develops investigational treatments for Central Nervous System (CNS) disorders. The company's primary focus is on its lead drug candidate, simufilam, a proprietary oral small molecule. Simufilam is designed to modulate the activity of the filamin A (FLNA) protein, which is involved in regulating neuronal development. The development program for simufilam targets conditions such as tuberous sclerosis complex (TSC)-related epilepsy and other mTOR pathway disorders. Preclinical studies in TSC models have shown that simufilam may reduce seizure frequency, supporting plans for future clinical trials.

Recent filings

Filing Released Lang Actions
8-K - FILANA THERAPEUTICS, INC. (0001069530) (Filer)
Regulatory Filings
2026-04-28 English
8-K - CASSAVA SCIENCES INC (0001069530) (Filer)
Regulatory Filings
2026-02-19 English
FORM 8-K
Regulatory Filings
2025-12-23 English
FORM 8-K/A
Regulatory Filings
2025-12-22 English
FORM 8-K
Regulatory Filings
2025-12-18 English
FORM 8-K
Regulatory Filings
2025-12-17 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.